Floatz logo

Inno-206

Beta Thalassemia Major

M.D. Anderson Cancer CenterEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Beta Thalassemia Major cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
M.D. Anderson Cancer Center
Phase 2BB
FILGRASTIM
Beni-Suef University
Phase 2/3BB
AMLODIPINE
Tanta University
Phase 2/3B
Sofosbuvir
Ain Shams University
Phase 3B
Ledipasvir
Ain Shams University
Phase 3B

View all 14 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →